DA-1726 Cuts Liver Fat 68.1% Placebo-Adjusted in Interim Phase 1 Data
MTVA sits 45% above its 52-week low of $0.966.
Summary
MetaVia's DA-1726 delivered a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at roughly 16 weeks in interim Phase 1 data. That follows the 8-K filed November 5th that first disclosed the 68% liver fat and 13.5% weight loss figures, and the November 12th uric acid readout (1.47 mg/dL placebo-adjusted, p<0.001) from the same study. The efficacy numbers are strong for an early-stage asset, but this is still Phase 1 — no Phase 2 results exist yet. Management targets a Phase 2 study of up to 150 subjects to begin in the second half of 2027, with full Phase 1 Parts 3A and 3B data expected in Q1 2027. With a micro-cap valuation and a going-concern warning in the last 10-Q, the stock is highly sensitive to clinical headlines and any future capital raise.
At the time of this announcement, MTVA was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.